At least 16 biotechs and pharmas are slated to report earnings this week. The Street is expecting revenues from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to increase by 18% to $502.8 million on strong sales of ophthalmic drug Eylea aflibercept. However, EPS is expected to decline as R&D spending has accelerated. Regeneron reported a 28% increase in R&D expenses to $367.8 million in 1H13. 3Q12 revenues included $65 million in milestones payments from partners Bayer AG (Xetra:BAYN) and Sanofi (Euronext:SAN; NYSE:SNY).

The Street will also be looking for details from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on the performance of obesity drug Belviq lorcaserin, which was